Bioamber (BIOA) Shares Gap Up to $0.41

Shares of Bioamber Inc (NYSE:BIOA) gapped up before the market opened on Friday . The stock had previously closed at $0.39, but opened at $0.41. Bioamber shares last traded at $0.44, with a volume of 2683100 shares.

Several research firms have recently weighed in on BIOA. ValuEngine cut Bioamber from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Cowen restated a “hold” rating and set a $1.00 price target on shares of Bioamber in a report on Friday, November 10th. Zacks Investment Research upgraded Bioamber from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Bioamber in a report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. Bioamber presently has an average rating of “Hold” and an average price target of $6.50.

The stock has a market cap of $23.19, a price-to-earnings ratio of -0.57 and a beta of 2.65. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.08 and a quick ratio of 0.75.

Large investors have recently added to or reduced their stakes in the company. Robecosam AG grew its holdings in shares of Bioamber by 82.9% during the third quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock worth $741,000 after purchasing an additional 670,000 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Bioamber by 336.2% in the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after acquiring an additional 41,701 shares during the period. FMR LLC lifted its stake in shares of Bioamber by 1.9% in the second quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock worth $3,495,000 after acquiring an additional 25,000 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Bioamber by 9.9% in the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after acquiring an additional 27,278 shares during the period. Institutional investors own 29.97% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Bioamber (BIOA) Shares Gap Up to $0.41” was first published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/14/bioamber-bioa-shares-gap-up-to-0-41.html.

About Bioamber

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply